Roche Holding AG (SWX:RO)
278.60
-1.60 (-0.57%)
Jun 17, 2025, 5:31 PM CET
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B
Revenue Growth
+3.23%
P/S Ratio
3.36
Revenue / Employee
604.32K
Employees
103,249
Market Cap
209.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 47.05B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Roche Holding AG News
- 15 hours ago - Roche And Prothena: Why Moving On Makes Sense - Seeking Alpha
- 1 day ago - Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue - Seeking Alpha
- 1 day ago - Genentech Provides Update on Phase III Verona Study - Business Wire
- 1 day ago - Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies - Seeking Alpha
- 1 day ago - Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures - WSJ
- 2 days ago - Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease - Benzinga
- 2 days ago - Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 2 days ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Benzinga